A selective high affinity ligand (SHAL) designed to bind to an over-expressed human antigen on non-Hodgkin's lymphoma also binds to canine B-cell lymphomas

Rod L. Balhorn, Katherine A Skorupski, Saphon Hok, Monique Cosman Balhorn, Teri Guerrero, Robert B Rebhun

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Therapies using antibodies directed against cell surface proteins have improved survival for human patients with non-Hodgkin's lymphoma (NHL). It is possible that similar immuno-therapeutic approaches may also benefit canine NHL patients. Unfortunately, variability between human and canine epitopes often limits the usefulness of such therapies in pet dogs. The Lym-1 antibody recognizes a unique epitope on HLA-DR10 that is expressed on the majority of human B-cell malignancies. The Lym-1 antibody has now been observed to bind to dog lymphocytes and B-cell NHL. Sequence comparisons and computer modeling of a human and three canine DRB1 proteins identified several orthologs of human HLA-DR10 expressed by dog lymphocytes. Immuno-staining confirmed the presence of proteins containing the Lym-1 epitope on dog lymphocytes and B-cell NHL. In addition, a selective high affinity ligand (SHAL) SH-7139 designed to bind within the Lym-1 epitope of HLA-DR10 was also observed to bind to canine B-cell NHL tissue. This SHAL, which is selectively cytotoxic to cells expressing HLA-DR10 and has been shown to cure mice bearing human B-cell lymphoma xenografts, may prove useful in treating B-cell malignancies in pet dogs.

Original languageEnglish (US)
Pages (from-to)235-242
Number of pages8
JournalVeterinary Immunology and Immunopathology
Volume137
Issue number3-4
DOIs
StatePublished - Oct 2010

Fingerprint

non-Hodgkin lymphoma
B-Cell Lymphoma
lymphoma
Non-Hodgkin's Lymphoma
B-lymphocytes
Canidae
Ligands
antigens
Antigens
Dogs
dogs
Epitopes
epitopes
Lymphocytes
Antibodies
Animal Assisted Therapy
B-Lymphocytes
lymphocytes
therapeutics
pets

Keywords

  • Canine
  • HLA
  • Lym-1
  • Lymphoma
  • Non-Hodgkin's

ASJC Scopus subject areas

  • Immunology
  • veterinary(all)

Cite this

A selective high affinity ligand (SHAL) designed to bind to an over-expressed human antigen on non-Hodgkin's lymphoma also binds to canine B-cell lymphomas. / Balhorn, Rod L.; Skorupski, Katherine A; Hok, Saphon; Balhorn, Monique Cosman; Guerrero, Teri; Rebhun, Robert B.

In: Veterinary Immunology and Immunopathology, Vol. 137, No. 3-4, 10.2010, p. 235-242.

Research output: Contribution to journalArticle

@article{0eb47775d52a445492e451a8f8535917,
title = "A selective high affinity ligand (SHAL) designed to bind to an over-expressed human antigen on non-Hodgkin's lymphoma also binds to canine B-cell lymphomas",
abstract = "Therapies using antibodies directed against cell surface proteins have improved survival for human patients with non-Hodgkin's lymphoma (NHL). It is possible that similar immuno-therapeutic approaches may also benefit canine NHL patients. Unfortunately, variability between human and canine epitopes often limits the usefulness of such therapies in pet dogs. The Lym-1 antibody recognizes a unique epitope on HLA-DR10 that is expressed on the majority of human B-cell malignancies. The Lym-1 antibody has now been observed to bind to dog lymphocytes and B-cell NHL. Sequence comparisons and computer modeling of a human and three canine DRB1 proteins identified several orthologs of human HLA-DR10 expressed by dog lymphocytes. Immuno-staining confirmed the presence of proteins containing the Lym-1 epitope on dog lymphocytes and B-cell NHL. In addition, a selective high affinity ligand (SHAL) SH-7139 designed to bind within the Lym-1 epitope of HLA-DR10 was also observed to bind to canine B-cell NHL tissue. This SHAL, which is selectively cytotoxic to cells expressing HLA-DR10 and has been shown to cure mice bearing human B-cell lymphoma xenografts, may prove useful in treating B-cell malignancies in pet dogs.",
keywords = "Canine, HLA, Lym-1, Lymphoma, Non-Hodgkin's",
author = "Balhorn, {Rod L.} and Skorupski, {Katherine A} and Saphon Hok and Balhorn, {Monique Cosman} and Teri Guerrero and Rebhun, {Robert B}",
year = "2010",
month = "10",
doi = "10.1016/j.vetimm.2010.05.014",
language = "English (US)",
volume = "137",
pages = "235--242",
journal = "Veterinary Immunology and Immunopathology",
issn = "0165-2427",
publisher = "Elsevier",
number = "3-4",

}

TY - JOUR

T1 - A selective high affinity ligand (SHAL) designed to bind to an over-expressed human antigen on non-Hodgkin's lymphoma also binds to canine B-cell lymphomas

AU - Balhorn, Rod L.

AU - Skorupski, Katherine A

AU - Hok, Saphon

AU - Balhorn, Monique Cosman

AU - Guerrero, Teri

AU - Rebhun, Robert B

PY - 2010/10

Y1 - 2010/10

N2 - Therapies using antibodies directed against cell surface proteins have improved survival for human patients with non-Hodgkin's lymphoma (NHL). It is possible that similar immuno-therapeutic approaches may also benefit canine NHL patients. Unfortunately, variability between human and canine epitopes often limits the usefulness of such therapies in pet dogs. The Lym-1 antibody recognizes a unique epitope on HLA-DR10 that is expressed on the majority of human B-cell malignancies. The Lym-1 antibody has now been observed to bind to dog lymphocytes and B-cell NHL. Sequence comparisons and computer modeling of a human and three canine DRB1 proteins identified several orthologs of human HLA-DR10 expressed by dog lymphocytes. Immuno-staining confirmed the presence of proteins containing the Lym-1 epitope on dog lymphocytes and B-cell NHL. In addition, a selective high affinity ligand (SHAL) SH-7139 designed to bind within the Lym-1 epitope of HLA-DR10 was also observed to bind to canine B-cell NHL tissue. This SHAL, which is selectively cytotoxic to cells expressing HLA-DR10 and has been shown to cure mice bearing human B-cell lymphoma xenografts, may prove useful in treating B-cell malignancies in pet dogs.

AB - Therapies using antibodies directed against cell surface proteins have improved survival for human patients with non-Hodgkin's lymphoma (NHL). It is possible that similar immuno-therapeutic approaches may also benefit canine NHL patients. Unfortunately, variability between human and canine epitopes often limits the usefulness of such therapies in pet dogs. The Lym-1 antibody recognizes a unique epitope on HLA-DR10 that is expressed on the majority of human B-cell malignancies. The Lym-1 antibody has now been observed to bind to dog lymphocytes and B-cell NHL. Sequence comparisons and computer modeling of a human and three canine DRB1 proteins identified several orthologs of human HLA-DR10 expressed by dog lymphocytes. Immuno-staining confirmed the presence of proteins containing the Lym-1 epitope on dog lymphocytes and B-cell NHL. In addition, a selective high affinity ligand (SHAL) SH-7139 designed to bind within the Lym-1 epitope of HLA-DR10 was also observed to bind to canine B-cell NHL tissue. This SHAL, which is selectively cytotoxic to cells expressing HLA-DR10 and has been shown to cure mice bearing human B-cell lymphoma xenografts, may prove useful in treating B-cell malignancies in pet dogs.

KW - Canine

KW - HLA

KW - Lym-1

KW - Lymphoma

KW - Non-Hodgkin's

UR - http://www.scopus.com/inward/record.url?scp=77956263753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956263753&partnerID=8YFLogxK

U2 - 10.1016/j.vetimm.2010.05.014

DO - 10.1016/j.vetimm.2010.05.014

M3 - Article

C2 - 20576295

AN - SCOPUS:77956263753

VL - 137

SP - 235

EP - 242

JO - Veterinary Immunology and Immunopathology

JF - Veterinary Immunology and Immunopathology

SN - 0165-2427

IS - 3-4

ER -